Cytokinetics Inc (CYTK) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cytokinetics reported revenue of $88.0M, up 376.6% from $18.5M the year before. Net income was -$785.0M (a -891.6% net margin), or -$6.54 per diluted share. Operating margin was -695.4%. Operating activities generated -$510.0M of cash, leaving -$534.8M of free cash flow. At fiscal year end, Cytokinetics held $1.42B in total assets against $2.08B in total liabilities, including $122.5M of cash and equivalents.
Open the full interactive Cytokinetics financials → Quarterly statements, key ratios, valuation history and price charts.
Cytokinetics Key Stats
| Share Price | $61.62 |
|---|---|
| Market Cap | $8.14B |
| Revenue YoY Growth | +376.6% |
| 52-Week Range | $54.76 – $87.26 |
| Shares Outstanding | 132.1 million (basic, 2026 Q2) |
Cytokinetics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Operating Income | -$93.9M | -$186.3M | -$324.2M | -$496.2M | -$536.2M | -$612.3M |
| Pre-Tax Income | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Diluted EPS | -$1.97 | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
Cytokinetics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.9M | $17.8M | $19.4M | $28.6M |
| Net Income | -$306.2M | -$183.0M | -$206.0M | -$198.8M |
| Diluted EPS | -$2.55 | -$1.52 | -$1.67 | -$1.50 |
Cytokinetics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.0M | $112.7M | $65.6M | $113.0M | $94.9M | $122.5M |
| Current Assets | $474.2M | $535.7M | $795.2M | $628.1M | $1.11B | $917.0M |
| Total Assets | $533.8M | $841.3M | $1.01B | $824.3M | $1.40B | $1.42B |
| Current Liabilities | $31.2M | $71.9M | $84.6M | $102.7M | $179.7M | $202.5M |
| Total Long-Term Debt | $46.2M | $47.4M | $649.6M | $68.5M | $104.7M | $287.6M |
| Total Liabilities | $420.4M | $597.5M | $1.12B | $1.21B | $1.54B | $2.08B |
| Shareholders' Equity | $113.4M | $243.9M | -$107.9M | -$386.3M | -$135.4M | -$659.6M |
Cytokinetics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $8.9M | -$142.5M | -$299.5M | -$414.3M | -$395.9M | -$510.0M |
| Cash From Investing | -$196.5M | -$147.8M | -$262.1M | $239.3M | -$553.1M | $16.7M |
| Cash From Financing | $234.1M | $320.0M | $516.2M | $221.3M | $930.6M | $524.5M |
| Free Cash Flow | -$2.2M | -$191.4M | -$310.8M | -$415.7M | -$399.8M | -$534.8M |
Figures from Cytokinetics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cytokinetics financials page for every line item.
Cytokinetics Company Profile
| Ticker | CYTK |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001061983 |
Frequently Asked Questions
What was Cytokinetics' revenue in fiscal 2025?
Cytokinetics (CYTK) reported revenue of $88.0M for fiscal 2025.
What is Cytokinetics' annual revenue history?
Cytokinetics' annual revenue by fiscal year: 2020: $55.8M; 2021: $70.4M; 2022: $94.6M; 2023: $7.5M; 2024: $18.5M; 2025: $88.0M.
What was Cytokinetics' net income in fiscal 2025?
Cytokinetics reported net income of -$785.0M for fiscal 2025.
What was Cytokinetics' earnings per share (EPS) in fiscal 2025?
Cytokinetics' diluted EPS was -$6.54 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cytokinetics generate in fiscal 2025?
Cytokinetics generated -$534.8M of free cash flow in fiscal 2025.
What was Cytokinetics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cytokinetics reported revenue of $28.6M.
How much debt does Cytokinetics have?
Cytokinetics reported $287.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cytokinetics are outstanding?
Cytokinetics reported a weighted average of 132.1 million basic shares outstanding in 2026 Q2.
What is Cytokinetics' market cap?
Based on its latest closing price, Cytokinetics (CYTK) has a market capitalization of about $8.14B.
When does Cytokinetics' fiscal year end?
Cytokinetics' fiscal year end, as registered with the SEC, is December 31.
Where is Cytokinetics headquartered?
Cytokinetics lists its business address in South San Francisco, California in its SEC filings.